The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Aged, 80 and over
Allografts
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bortezomib
/ administration & dosage
Breast Neoplasms
Combined Modality Therapy
Dendritic Cells
Dexamethasone
/ administration & dosage
Drug Synergism
Fatal Outcome
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunophenotyping
Lenalidomide
/ administration & dosage
Male
Middle Aged
Neoplasms, Glandular and Epithelial
/ drug therapy
Neoplasms, Second Primary
/ drug therapy
Off-Label Use
Skin Neoplasms
/ drug therapy
blastic plasmacytoid dendritic cell neoplasm
bortezomib
lenalidomide
leukemia
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
02
07
2019
revised:
22
08
2019
accepted:
24
08
2019
pubmed:
30
8
2019
medline:
20
11
2019
entrez:
30
8
2019
Statut:
ppublish
Résumé
We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemotherapy, we observed two complete responses and one clinical remission. Together with the encouraging literature data on the effects of lenalidomide and bortezomib on BPDCN cells, our results might prompt further investigations of this regimen's value in BPDCN.
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
487-489Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
Agliano A, Martin-Padura I, Marighetti P, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163-6173.
Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606-1616.
Philippe L, Ceroi A, Bôle-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102(11):1861-1868.